

Package leaflet: Information for the user
Comirnaty LP.8.1 30 micrograms/dose dispersion for injection (frozen vials)
Adults and adolescents from 12 years
COVID-19 mRNA Vaccine
mRNA encoding LP.8.1

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Comirnaty LP.8.1 is and what it is used for
2. What you need to know before you receive Comirnaty LP.8.1
3. How Comirnaty LP.8.1 is given
4. Possible side effects
5. How to store Comirnaty LP.8.1
6. Contents of the pack and other information

1. What Comirnaty LP.8.1 is and what it is used for

Comirnaty LP.8.1 is a vaccine used for preventing COVID-19 caused by SARS-CoV-2.

Comirnaty LP.8.1 30 micrograms/dose dispersion for injection is given to adults and adolescents from 12 years of age and older.

The vaccine causes the immune system (the body's natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.

As Comirnaty LP.8.1 does not contain the virus to produce immunity, it cannot give you COVID-19.

The use of this vaccine should be in accordance with official recommendations.

2. What you need to know before you receive Comirnaty LP.8.1

Comirnaty LP.8.1 should not be given

- if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you are given the vaccine if:

- you have ever had a severe allergic reaction or breathing problems after any other vaccine injection or after you were given this vaccine in the past.
- you are feeling nervous about the vaccination process or have ever fainted following any needle injection.

- you have a severe illness or infection with high fever. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold.
- you have a bleeding problem, you bruise easily or you use a medicine to prevent blood-clots.
- you have a weakened immune system, because of a disease such as HIV infection or a medicine such as corticosteroid that affects your immune system.

There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) after vaccination with Comirnaty (see section 4). These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. The risk of myocarditis and pericarditis seems lower in children ages 5 to 11 years compared with ages 12 to 17 years. Most cases of myocarditis and pericarditis recover. Some cases required intensive care support and fatal cases have been seen. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur.

As with any vaccine, Comirnaty LP.8.1 may not fully protect all those who receive it and it is not known how long you will be protected.

The efficacy of Comirnaty LP.8.1 may be lower in people who are immunocompromised. If you are immunocompromised, you may receive additional doses of Comirnaty LP.8.1. In these cases, you should continue to maintain physical precautions to help prevent COVID-19. In addition, your close contacts should be vaccinated as appropriate. Discuss appropriate individual recommendations with your doctor.

Children

Comirnaty LP.8.1 30 micrograms/dose dispersion for injection is not recommended for children aged under 12 years.

There are paediatric formulations available for infants aged 6 months and above and children below 12 years of age. For details, please refer to the Package Leaflet for other formulations.

The vaccine is not recommended for infants aged under 6 months.

Other medicines and Comirnaty LP.8.1

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines or have recently received any other vaccine.

Comirnaty LP.8.1 may be given at the same time as a flu vaccine.

In adults 18 years of age and older, Comirnaty LP.8.1 may be given at the same time as a pneumococcal conjugated vaccine (PCV).

In adults 18 years of age and older, Comirnaty LP.8.1 may be given at the same time as a respiratory syncytial virus (RSV) vaccine.

In older adults 65 years of age and older, Comirnaty LP.8.1 may be given at the same time as a high dose flu and an RSV vaccine.

Pregnancy and breast-feeding

If you are pregnant or think you may be pregnant, tell your doctor, nurse or pharmacist before you receive this vaccine.

No data are available yet regarding the use of Comirnaty LP.8.1 during pregnancy. However, a large amount of information from pregnant women vaccinated with the initially approved Comirnaty

vaccine during the second and third trimester have not shown negative effects on the pregnancy or the newborn baby. While information on effects on pregnancy or the newborn baby after vaccination during the first trimester is limited, no change to the risk for miscarriage has been seen. Comirnaty LP.8.1 can be used during pregnancy.

No data are available yet regarding the use of Comirnaty LP.8.1 during breast-feeding. However, no effects on the breastfed newborn/infant are anticipated. Data from women who were breast-feeding after vaccination with the initially approved Comirnaty vaccine have not shown a risk for adverse effects in breastfed newborns/infants. Comirnaty LP.8.1 can be used while breast-feeding.

Driving and using machines

Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your ability to drive or use machines. Wait until these effects have worn off before you drive or use machines.

3. How Comirnaty LP.8.1 is given

Comirnaty LP.8.1 is given as an injection of 0.3 mL into a muscle of your upper arm.

You will receive 1 injection, regardless whether you have received a COVID-19 vaccine before.

If you were previously vaccinated with a COVID-19 vaccine, you should not receive a dose of Comirnaty LP.8.1 until at least 3 months after the most recent dose.

If you are immunocompromised, you may receive additional doses of Comirnaty LP.8.1.

If you have any further questions on the use of Comirnaty LP.8.1, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all vaccines, Comirnaty LP.8.1 can cause side effects, although not everybody gets them.

Very common side effects: may affect more than 1 in 10 people

- injection site: pain, swelling
- tiredness, headache
- muscle pain, joint pain
- chills, fever
- diarrhoea

Some of these side effects were slightly more frequent in adolescents 12 to 15 years than in adults.

Common side effects: may affect up to 1 in 10 people

- nausea
- vomiting ('very common' in pregnant women 18 years of age and older and in immunocompromised individuals 12 to 18 years of age)
- injection site redness ('very common' in immunocompromised individuals 12 years of age and older)
- enlarged lymph nodes (more frequently observed after a booster dose)

Uncommon side effects: may affect up to 1 in 100 people

- feeling unwell, feeling weak or lack of energy/sleepy
- arm pain
- insomnia

- injection site itching
- allergic reactions such as rash or itching
- decreased appetite
- dizziness
- excessive sweating, night sweats

Rare side effects: may affect up to 1 in 1 000 people

- temporary one sided facial drooping
- allergic reactions such as hives or swelling of the face

Very rare side effects: may affect up to 1 in 10 000 people

- inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart (pericarditis) which can result in breathlessness, palpitations or chest pain

Not known (cannot be estimated from the available data)

- severe allergic reaction
- extensive swelling of the vaccinated limb
- swelling of the face (swelling of the face may occur in patients who have had facial dermatological fillers)
- a skin reaction that causes red spots or patches on the skin, that may look like a target or “bulls-eye” with a dark red centre surrounded by paler red rings (erythema multiforme)
- unusual feeling in the skin, such as tingling or a crawling feeling (paraesthesia)
- decreased feeling or sensitivity, especially in the skin (hypoesthesia)
- heavy menstrual bleeding (most cases appeared to be non-serious and temporary in nature)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via HPRa Pharmacovigilance. Website: www.hpra.ie

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Comirnaty LP.8.1

Keep this medicine out of the sight and reach of children.

The following information about storage, expiry and use and handling is intended for healthcare professionals.

Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.

Store in freezer at -90 °C to -60 °C.

Store in the original package in order to protect from light.

The vaccine will be received frozen at -90 °C to -60 °C. Frozen vaccine can be stored either at -90 °C to -60 °C or 2 °C to 8 °C upon receipt.

When stored frozen at -90 °C to -60 °C, 10-vial packs of the vaccine can be thawed at 2 °C to 8 °C for 6 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Thawed (previously frozen) vials: Once removed from the freezer, the unopened vial may be stored and transported refrigerated at 2 °C to 8 °C for up to 10 weeks; not exceeding the printed expiry date

(EXP). The outer carton should be marked with the new expiry date at 2 °C to 8 °C. Once thawed, the vaccine cannot be re-frozen.

Prior to use, the unopened vials can be stored for up to 12 hours at temperatures between 8 °C and 30 °C.

Thawed vials can be handled in room light conditions.

Opened vials: After first puncture, store the vaccine at 2 °C to 30 °C and use within 12 hours, which includes up to 6 hours transportation time. Discard any unused vaccine.

Do not use this vaccine if you notice particulates or discolouration.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Comirnaty LP.8.1 contains

- The active substance of COVID-19 mRNA Vaccine (nucleoside modified) is called mRNA encoding LP.8.1.
 - A multidose vial contains 6 doses of 0.3 mL with 30 micrograms mRNA encoding LP.8.1 each.
- The other ingredients are:
 - ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
 - 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
 - 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)
 - cholesterol
 - trometamol
 - trometamol hydrochloride
 - sucrose
 - water for injections

What Comirnaty LP.8.1 looks like and contents of the pack

The vaccine is a white to off-white dispersion (pH: 6.9 - 7.9) provided in a multidose vial of 6 doses in a 2 mL clear vial (type I glass), with a rubber stopper and a grey flip-off plastic cap with aluminium seal.

Multidose vials pack size: 10 vials

Marketing Authorisation Holder

BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz
Germany
Phone: +49 6131 9084-0
Fax: +49 6131 9084-2121
service@biontech.de

Manufacturers

BioNTech Manufacturing GmbH
Kupferbergterrasse 17 - 19
55116 Mainz
Germany

Pfizer Manufacturing Belgium NV
Rijksweg 12
Puurs-Sint-Amands, 2870
Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Ireland: Pfizer Healthcare Ireland, Tel: 1800 633 363 (toll free), +44 (0)1304 616161

This leaflet was last revised in 07/2025.

Scan the code with a mobile device to get the package leaflet in different languages.



URL: www.comirnatyglobal.com

Detailed information on this medicine is available on the European Medicines Agency website:
<https://www.ema.europa.eu>.

Ref: bCY (LP.8.1) 30 mcg MDV 1_0

The following information is intended for healthcare professionals only:

Administer Comirnaty LP.8.1 intramuscularly as a single dose of 0.3 mL regardless of prior COVID-19 vaccination status.

For individuals who have previously been vaccinated with a COVID-19 vaccine, Comirnaty LP.8.1 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine.

Additional doses may be given to individuals who are severely immunocompromised.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Handling instructions prior to use for frozen vials

Comirnaty LP.8.1 should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

- **Verify** that the vial has a **grey plastic cap** and the product **name is Comirnaty LP.8.1 30 micrograms/dose dispersion for injection** (12 years and older).
- If the vial has another product name on the label, please make reference to the Summary of Product Characteristics for that formulation.
- If the vial is stored frozen it must be thawed prior to use. Frozen vials should be transferred to an environment of 2 °C to 8 °C to thaw. Ensure vials are completely thawed prior to use. A 10-vial pack of multidose vials may take 6 hours to thaw.
- Upon moving vials to 2 °C to 8 °C storage, update the expiry date on the carton.
- Unopened vials can be **stored for up to 10 weeks at 2 °C to 8 °C**; not exceeding the printed expiry date (EXP).
- Alternatively, individual frozen vials may be thawed for 30 minutes at temperatures up to 30 °C.

- Prior to use, the unopened vial can be stored for up to 12 hours at temperatures up to 30 °C. Thawed vials can be handled in room light conditions.

Preparation of 0.3 mL doses

- Gently mix by inverting vials 10 times prior to use. Do not shake.
- Prior to mixing, the thawed dispersion may contain white to off-white opaque amorphous particles.
- After mixing, the vaccine should present as a white to off-white dispersion with no particulates visible. Do not use the vaccine if particulates or discolouration are present.
- Using aseptic technique, cleanse the vial stopper with a single use antiseptic swab.
- Withdraw 0.3 mL of Comirnaty LP.8.1.
- **Low dead-volume syringes and/or needles** should be used in order to extract 6 doses from a single vial. The low dead-volume syringe and needle combination should have a dead-volume of no more than 35 microlitres. If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial.
- Each dose must contain 0.3 mL of vaccine.
- If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
- Record the appropriate date/time on the vial. Discard any unused vaccine 12 hours after first puncture.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Package leaflet: Information for the user

Comirnaty KP.2 30 micrograms/dose dispersion for injection (frozen vials) Adults and adolescents from 12 years COVID-19 mRNA Vaccine cemivameran

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Comirnaty KP.2 is and what it is used for
2. What you need to know before you receive Comirnaty KP.2
3. How Comirnaty KP.2 is given
4. Possible side effects
5. How to store Comirnaty KP.2
6. Contents of the pack and other information

1. What Comirnaty KP.2 is and what it is used for

Comirnaty KP.2 is a vaccine used for preventing COVID-19 caused by SARS-CoV-2.

Comirnaty KP.2 30 micrograms/dose dispersion for injection is given to adults and adolescents from 12 years of age and older.

The vaccine causes the immune system (the body's natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.

As Comirnaty KP.2 does not contain the virus to produce immunity, it cannot give you COVID-19.

The use of this vaccine should be in accordance with official recommendations.

2. What you need to know before you receive Comirnaty KP.2

Comirnaty KP.2 should not be given

- if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you are given the vaccine if:

- you have ever had a severe allergic reaction or breathing problems after any other vaccine injection or after you were given this vaccine in the past.
- you are feeling nervous about the vaccination process or have ever fainted following any needle injection.

- you have a severe illness or infection with high fever. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold.
- you have a bleeding problem, you bruise easily or you use a medicine to prevent blood-clots.
- you have a weakened immune system, because of a disease such as HIV infection or a medicine such as corticosteroid that affects your immune system.

There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) after vaccination with Comirnaty (see section 4). These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. The risk of myocarditis and pericarditis seems lower in children ages 5 to 11 years compared with ages 12 to 17 years. Most cases of myocarditis and pericarditis recover. Some cases required intensive care support and fatal cases have been seen. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur.

As with any vaccine, Comirnaty KP.2 may not fully protect all those who receive it and it is not known how long you will be protected.

The efficacy of Comirnaty KP.2 may be lower in people who are immunocompromised. If you are immunocompromised, you may receive additional doses of Comirnaty KP.2. In these cases, you should continue to maintain physical precautions to help prevent COVID-19. In addition, your close contacts should be vaccinated as appropriate. Discuss appropriate individual recommendations with your doctor.

Children

Comirnaty KP.2 30 micrograms/dose dispersion for injection is not recommended for children aged under 12 years.

There are paediatric formulations available for infants aged 6 months and above and children below 12 years of age. For details, please refer to the Package Leaflet for other formulations.

The vaccine is not recommended for infants aged under 6 months.

Other medicines and Comirnaty KP.2

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines or have recently received any other vaccine.

Comirnaty KP.2 may be given at the same time as a flu vaccine.

In adults 18 years of age and older, Comirnaty KP.2 may be given at the same time as a pneumococcal conjugated vaccine (PCV).

In adults 18 years of age and older, Comirnaty KP.2 may be given at the same time as a respiratory syncytial virus (RSV) vaccine.

In older adults 65 years of age and older, Comirnaty KP.2 may be given at the same time as a high dose flu and an RSV vaccine.

Pregnancy and breast-feeding

If you are pregnant or think you may be pregnant, tell your doctor, nurse or pharmacist before you receive this vaccine.

No data are available yet regarding the use of Comirnaty KP.2 during pregnancy. However, a large amount of information from pregnant women vaccinated with the initially approved Comirnaty vaccine during the second and third trimester have not shown negative effects on the pregnancy or the newborn baby. While information on effects on pregnancy or the newborn baby after vaccination during the first trimester is limited, no change to the risk for miscarriage has been seen. Comirnaty KP.2 can be used during pregnancy.

No data are available yet regarding the use of Comirnaty KP.2 during breast-feeding. However, no effects on the breastfed newborn/infant are anticipated. Data from women who were breast-feeding after vaccination with the initially approved Comirnaty vaccine have not shown a risk for adverse effects in breastfed newborns/infants. Comirnaty KP.2 can be used while breast-feeding.

Driving and using machines

Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your ability to drive or use machines. Wait until these effects have worn off before you drive or use machines.

3. How Comirnaty KP.2 is given

Comirnaty KP.2 is given as an injection of 0.3 mL into a muscle of your upper arm.

You will receive 1 injection, regardless whether you have received a COVID-19 vaccine before.

If you were previously vaccinated with a COVID-19 vaccine, you should not receive a dose of Comirnaty KP.2 until at least 3 months after the most recent dose.

If you are immunocompromised, you may receive additional doses of Comirnaty KP.2.

If you have any further questions on the use of Comirnaty KP.2, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all vaccines, Comirnaty KP.2 can cause side effects, although not everybody gets them.

Very common side effects: may affect more than 1 in 10 people

- injection site: pain, swelling
- tiredness, headache
- muscle pain, joint pain
- chills, fever
- diarrhoea

Some of these side effects were slightly more frequent in adolescents 12 to 15 years than in adults.

Common side effects: may affect up to 1 in 10 people

- nausea
- vomiting ('very common' in pregnant women 18 years of age and older and in immunocompromised individuals 12 to 18 years of age)
- injection site redness ('very common' in immunocompromised individuals 12 years of age and older)
- enlarged lymph nodes (more frequently observed after a booster dose)

Uncommon side effects: may affect up to 1 in 100 people

- feeling unwell, feeling weak or lack of energy/sleepy
- arm pain
- insomnia
- injection site itching
- allergic reactions such as rash or itching
- decreased appetite
- dizziness
- excessive sweating, night sweats

Rare side effects: may affect up to 1 in 1 000 people

- temporary one sided facial drooping
- allergic reactions such as hives or swelling of the face

Very rare side effects: may affect up to 1 in 10 000 people

- inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart (pericarditis) which can result in breathlessness, palpitations or chest pain

Not known (cannot be estimated from the available data)

- severe allergic reaction
- extensive swelling of the vaccinated limb
- swelling of the face (swelling of the face may occur in patients who have had facial dermatological fillers)
- a skin reaction that causes red spots or patches on the skin, that may look like a target or “bulls-eye” with a dark red centre surrounded by paler red rings (erythema multiforme)
- unusual feeling in the skin, such as tingling or a crawling feeling (paraesthesia)
- decreased feeling or sensitivity, especially in the skin (hypoesthesia)
- heavy menstrual bleeding (most cases appeared to be non-serious and temporary in nature)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via HPRa Pharmacovigilance. Website: www.hpra.ie

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Comirnaty KP.2

Keep this medicine out of the sight and reach of children.

The following information about storage, expiry and use and handling is intended for healthcare professionals.

Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.

Store in freezer at -90 °C to -60 °C.

Store in the original package in order to protect from light.

The vaccine will be received frozen at -90 °C to -60 °C. Frozen vaccine can be stored either at -90 °C to -60 °C or 2 °C to 8 °C upon receipt.

Single dose vials: When stored frozen at -90 °C to -60 °C, 10-vial packs of single dose vials of the vaccine can be thawed at 2 °C to 8 °C for 2 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Multidose vials: When stored frozen at -90 °C to -60 °C, 10-vial packs of the vaccine can be thawed at 2 °C to 8 °C for 6 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Thawed (previously frozen) vials: Once removed from the freezer, the unopened vial may be stored and transported refrigerated at 2 °C to 8 °C for up to 10 weeks; not exceeding the printed expiry date (EXP). The outer carton should be marked with the new expiry date at 2 °C to 8 °C. Once thawed, the vaccine cannot be re-frozen.

Prior to use, the unopened vials can be stored for up to 12 hours at temperatures between 8 °C and 30 °C.

Thawed vials can be handled in room light conditions.

Opened vials: After first puncture, store the vaccine at 2 °C to 30 °C and use within 12 hours, which includes up to 6 hours transportation time. Discard any unused vaccine.

Do not use this vaccine if you notice particulates or discolouration.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Comirnaty KP.2 contains

- The active substance of COVID-19 mRNA Vaccine (nucleoside modified) is called cemivameran.
 - A single dose vial contains 1 dose of 0.3 mL with 30 micrograms cemivameran each.
 - A multidose vial contains 6 doses of 0.3 mL with 30 micrograms cemivameran each.
- The other ingredients are:
 - ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
 - 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
 - 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)
 - cholesterol
 - trometamol
 - trometamol hydrochloride
 - sucrose
 - water for injections

What Comirnaty KP.2 looks like and contents of the pack

The vaccine is a white to off-white dispersion (pH: 6.9 - 7.9) provided in either:

- A single dose vial of 1 dose in a 2 mL clear vial (type I glass), with a rubber stopper and a grey flip-off plastic cap with aluminium seal; or
- A multidose vial of 6 doses in a 2 mL clear vial (type I glass), with a rubber stopper and a grey flip-off plastic cap with aluminium seal.

Single dose vials pack size: 10 vials

Multidose vials pack size: 10 vials

Not all pack sizes may be marketed.

Marketing Authorisation Holder

BioNTech Manufacturing GmbH

An der Goldgrube 12

55131 Mainz

Germany

Phone: +49 6131 9084-0

Fax: +49 6131 9084-2121

service@biontech.de

Manufacturers

BioNTech Manufacturing GmbH

Kupferbergterrasse 17 - 19

55116 Mainz

Germany

Pfizer Manufacturing Belgium NV

Rijksweg 12

Puurs-Sint-Amands, 2870

Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Ireland: Pfizer Healthcare Ireland, Tel: 1800 633 363 (toll free), +44 (0)1304 616161

This leaflet was last revised in 05/2025.

Scan the code with a mobile device to get the package leaflet in different languages.



URL: www.comirnatyglobal.com

Detailed information on this medicine is available on the European Medicines Agency website:

<https://www.ema.europa.eu>.

The following information is intended for healthcare professionals only:

Administer Comirnaty KP.2 intramuscularly as a single dose of 0.3 mL regardless of prior COVID-19 vaccination status.

For individuals who have previously been vaccinated with a COVID-19 vaccine, Comirnaty KP.2 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine.

Additional doses may be given to individuals who are severely immunocompromised.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Handling instructions prior to use for frozen vials

Comirnaty KP.2 should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

- **Verify** that the vial has a **grey plastic cap** and the product **name is Comirnaty KP.2 30 micrograms/dose dispersion for injection** (12 years and older).
- If the vial has another product name on the label, please make reference to the Summary of Product Characteristics for that formulation.
- If the vial is stored frozen it must be thawed prior to use. Frozen vials should be transferred to an environment of 2 °C to 8 °C to thaw. Ensure vials are completely thawed prior to use.
 - Single dose vials: A 10-vial pack of single dose vials may take 2 hours to thaw.
 - Multidose vials: A 10-vial pack of multidose vials may take 6 hours to thaw.
- Upon moving vials to 2 °C to 8 °C storage, update the expiry date on the carton.
- Unopened vials can be **stored for up to 10 weeks at 2 °C to 8 °C**; not exceeding the printed expiry date (EXP).
- Alternatively, individual frozen vials may be thawed for 30 minutes at temperatures up to 30 °C.
- Prior to use, the unopened vial can be stored for up to 12 hours at temperatures up to 30 °C. Thawed vials can be handled in room light conditions.

Preparation of 0.3 mL doses

- Gently mix by inverting vials 10 times prior to use. Do not shake.
- Prior to mixing, the thawed dispersion may contain white to off-white opaque amorphous particles.
- After mixing, the vaccine should present as a white to off-white dispersion with no particulates visible. Do not use the vaccine if particulates or discolouration are present.
- Check whether the vial is a single dose vial or a multidose vial and follow the applicable handling instructions below:
 - Single dose vials
 - Withdraw a single 0.3 mL dose of vaccine.
 - Discard vial and any excess volume.
 - Multidose vials
 - Multidose vials contain 6 doses of 0.3 mL each.
 - Using aseptic technique, cleanse the vial stopper with a single use antiseptic swab.
 - Withdraw 0.3 mL of Comirnaty KP.2.
 - **Low dead-volume syringes and/or needles** should be used in order to extract 6 doses from a single vial. The low dead-volume syringe and needle combination should have a dead-volume of no more than 35 microlitres. If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial.
 - Each dose must contain 0.3 mL of vaccine.

- If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
- Record the appropriate date/time on the vial. Discard any unused vaccine 12 hours after first puncture.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Package leaflet: Information for the user

Comirnaty JN.1 30 micrograms/dose dispersion for injection (frozen vials) Adults and adolescents from 12 years COVID-19 mRNA Vaccine bretovameran

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Comirnaty JN.1 is and what it is used for
2. What you need to know before you receive Comirnaty JN.1
3. How Comirnaty JN.1 is given
4. Possible side effects
5. How to store Comirnaty JN.1
6. Contents of the pack and other information

1. What Comirnaty JN.1 is and what it is used for

Comirnaty JN.1 is a vaccine used for preventing COVID-19 caused by SARS-CoV-2.

Comirnaty JN.1 30 micrograms/dose dispersion for injection is given to adults and adolescents from 12 years of age and older.

The vaccine causes the immune system (the body's natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.

As Comirnaty JN.1 does not contain the virus to produce immunity, it cannot give you COVID-19.

The use of this vaccine should be in accordance with official recommendations.

2. What you need to know before you receive Comirnaty JN.1

Comirnaty JN.1 should not be given

- if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you are given the vaccine if:

- you have ever had a severe allergic reaction or breathing problems after any other vaccine injection or after you were given this vaccine in the past.
- you are feeling nervous about the vaccination process or have ever fainted following any needle injection.

- you have a severe illness or infection with high fever. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold.
- you have a bleeding problem, you bruise easily or you use a medicine to prevent blood-clots.
- you have a weakened immune system, because of a disease such as HIV infection or a medicine such as corticosteroid that affects your immune system.

There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) after vaccination with Comirnaty (see section 4). These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. The risk of myocarditis and pericarditis seems lower in children ages 5 to 11 years compared with ages 12 to 17 years. Most cases of myocarditis and pericarditis recover. Some cases required intensive care support and fatal cases have been seen. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur.

As with any vaccine, Comirnaty JN.1 may not fully protect all those who receive it and it is not known how long you will be protected.

The efficacy of Comirnaty JN.1 may be lower in people who are immunocompromised. If you are immunocompromised, you may receive additional doses of Comirnaty JN.1. In these cases, you should continue to maintain physical precautions to help prevent COVID-19. In addition, your close contacts should be vaccinated as appropriate. Discuss appropriate individual recommendations with your doctor.

Children

Comirnaty JN.1 30 micrograms/dose dispersion for injection is not recommended for children aged under 12 years.

There are paediatric formulations available for infants aged 6 months and above and children below 12 years of age. For details, please refer to the Package Leaflet for other formulations.

The vaccine is not recommended for infants aged under 6 months.

Other medicines and Comirnaty JN.1

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines or have recently received any other vaccine.

Comirnaty JN.1 may be given at the same time as a flu vaccine.

In adults 18 years of age and older, Comirnaty JN.1 may be given at the same time as a pneumococcal conjugated vaccine (PCV).

In adults 18 years of age and older, Comirnaty JN.1 may be given at the same time as a respiratory syncytial virus (RSV) vaccine.

In older adults 65 years of age and older, Comirnaty JN.1 may be given at the same time as a high dose flu and an RSV vaccine.

Pregnancy and breast-feeding

If you are pregnant or think you may be pregnant, tell your doctor, nurse or pharmacist before you receive this vaccine.

No data are available yet regarding the use of Comirnaty JN.1 during pregnancy. However, a large amount of information from pregnant women vaccinated with the initially approved Comirnaty vaccine during the second and third trimester have not shown negative effects on the pregnancy or the newborn baby. While information on effects on pregnancy or the newborn baby after vaccination during the first trimester is limited, no change to the risk for miscarriage has been seen. Comirnaty JN.1 can be used during pregnancy.

No data are available yet regarding the use of Comirnaty JN.1 during breast-feeding. However, no effects on the breastfed newborn/infant are anticipated. Data from women who were breast-feeding after vaccination with the initially approved Comirnaty vaccine have not shown a risk for adverse effects in breastfed newborns/infants. Comirnaty JN.1 can be used while breast-feeding.

Driving and using machines

Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your ability to drive or use machines. Wait until these effects have worn off before you drive or use machines.

3. How Comirnaty JN.1 is given

Comirnaty JN.1 is given as an injection of 0.3 mL into a muscle of your upper arm.

You will receive 1 injection, regardless whether you have received a COVID-19 vaccine before.

If you were previously vaccinated with a COVID-19 vaccine, you should not receive a dose of Comirnaty JN.1 until at least 3 months after the most recent dose.

If you are immunocompromised, you may receive additional doses of Comirnaty JN.1.

If you have any further questions on the use of Comirnaty JN.1, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all vaccines, Comirnaty JN.1 can cause side effects, although not everybody gets them.

Very common side effects: may affect more than 1 in 10 people

- injection site: pain, swelling
- tiredness, headache
- muscle pain, joint pain
- chills, fever
- diarrhoea

Some of these side effects were slightly more frequent in adolescents 12 to 15 years than in adults.

Common side effects: may affect up to 1 in 10 people

- nausea
- vomiting ('very common' in pregnant women 18 years of age and older and in immunocompromised individuals 12 to 18 years of age)
- injection site redness ('very common' in immunocompromised individuals 12 years of age and older)
- enlarged lymph nodes (more frequently observed after a booster dose)

Uncommon side effects: may affect up to 1 in 100 people

- feeling unwell, feeling weak or lack of energy/sleepy
- arm pain
- insomnia
- injection site itching
- allergic reactions such as rash or itching
- decreased appetite
- dizziness
- excessive sweating, night sweats

Rare side effects: may affect up to 1 in 1 000 people

- temporary one sided facial drooping
- allergic reactions such as hives or swelling of the face

Very rare side effects: may affect up to 1 in 10 000 people

- inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart (pericarditis) which can result in breathlessness, palpitations or chest pain

Not known (cannot be estimated from the available data)

- severe allergic reaction
- extensive swelling of the vaccinated limb
- swelling of the face (swelling of the face may occur in patients who have had facial dermatological fillers)
- a skin reaction that causes red spots or patches on the skin, that may look like a target or “bulls-eye” with a dark red centre surrounded by paler red rings (erythema multiforme)
- unusual feeling in the skin, such as tingling or a crawling feeling (paraesthesia)
- decreased feeling or sensitivity, especially in the skin (hypoesthesia)
- heavy menstrual bleeding (most cases appeared to be non-serious and temporary in nature)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via HPRA Pharmacovigilance. Website: www.hpra.ie

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Comirnaty JN.1

Keep this medicine out of the sight and reach of children.

The following information about storage, expiry and use and handling is intended for healthcare professionals.

Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.

Store in freezer at -90 °C to -60 °C.

Store in the original package in order to protect from light.

The vaccine will be received frozen at -90 °C to -60 °C. Frozen vaccine can be stored either at -90 °C to -60 °C or 2 °C to 8 °C upon receipt.

Single dose vials: When stored frozen at -90 °C to -60 °C, 10-vial packs of single dose vials of the vaccine can be thawed at 2 °C to 8 °C for 2 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Multidose vials: When stored frozen at -90 °C to -60 °C, 10-vial packs of the vaccine can be thawed at 2 °C to 8 °C for 6 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Thawed (previously frozen) vials: Once removed from the freezer, the unopened vial may be stored and transported refrigerated at 2 °C to 8 °C for up to 10 weeks; not exceeding the printed expiry date (EXP). The outer carton should be marked with the new expiry date at 2 °C to 8 °C. Once thawed, the vaccine cannot be re-frozen.

Prior to use, the unopened vials can be stored for up to 12 hours at temperatures between 8 °C and 30 °C.

Thawed vials can be handled in room light conditions.

Opened vials: After first puncture, store the vaccine at 2 °C to 30 °C and use within 12 hours, which includes up to 6 hours transportation time. Discard any unused vaccine.

Do not use this vaccine if you notice particulates or discolouration.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Comirnaty JN.1 contains

- The active substance of COVID-19 mRNA Vaccine (nucleoside modified) is called bretovamieran.
 - A single dose vial contains 1 dose of 0.3 mL with 30 micrograms bretovamieran each.
 - A multidose vial contains 6 doses of 0.3 mL with 30 micrograms bretovamieran each.
- The other ingredients are:
 - ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
 - 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
 - 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)
 - cholesterol
 - trometamol
 - trometamol hydrochloride
 - sucrose
 - water for injections

What Comirnaty JN.1 looks like and contents of the pack

The vaccine is a white to off-white dispersion (pH: 6.9 - 7.9) provided in either:

- A single dose vial of 1 dose in a 2 mL clear vial (type I glass), with a rubber stopper and a grey flip-off plastic cap with aluminium seal; or
- A multidose vial of 6 doses in a 2 mL clear vial (type I glass), with a rubber stopper and a grey flip-off plastic cap with aluminium seal.

Single dose vials pack size: 10 vials

Multidose vials pack size: 10 vials

Not all pack sizes may be marketed.

Marketing Authorisation Holder

BioNTech Manufacturing GmbH

An der Goldgrube 12

55131 Mainz

Germany

Phone: +49 6131 9084-0

Fax: +49 6131 9084-2121

service@biontech.de

Manufacturers

BioNTech Manufacturing GmbH

Kupferbergterrasse 17 - 19

55116 Mainz

Germany

Pfizer Manufacturing Belgium NV

Rijksweg 12

Puurs-Sint-Amands, 2870

Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Ireland: Pfizer Healthcare Ireland, Tel: 1800 633 363 (toll free), +44 (0)1304 616161

This leaflet was last revised in 05/2025.

Scan the code with a mobile device to get the package leaflet in different languages.



URL: www.comirnatyglobal.com

Detailed information on this medicine is available on the European Medicines Agency website:

<https://www.ema.europa.eu>.

The following information is intended for healthcare professionals only:

Administer Comirnaty JN.1 intramuscularly as a single dose of 0.3 mL regardless of prior COVID-19 vaccination status.

For individuals who have previously been vaccinated with a COVID-19 vaccine, Comirnaty JN.1 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine.

Additional doses may be given to individuals who are severely immunocompromised.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Handling instructions prior to use for frozen vials Comirnaty JN.1 should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

- **Verify** that the vial has a **grey plastic cap** and the product **name is Comirnaty JN.1 30 micrograms/dose dispersion for injection** (12 years and older).
- If the vial has another product name on the label, please make reference to the Summary of Product Characteristics for that formulation.
- If the vial is stored frozen it must be thawed prior to use. Frozen vials should be transferred to an environment of 2 °C to 8 °C to thaw. Ensure vials are completely thawed prior to use.
 - Single dose vials: A 10-vial pack of single dose vials may take 2 hours to thaw.
 - Multidose vials: A 10-vial pack of multidose vials may take 6 hours to thaw.
- Upon moving vials to 2 °C to 8 °C storage, update the expiry date on the carton.
- Unopened vials can be **stored for up to 10 weeks at 2 °C to 8 °C**; not exceeding the printed expiry date (EXP).
- Alternatively, individual frozen vials may be thawed for 30 minutes at temperatures up to 30 °C.
- Prior to use, the unopened vial can be stored for up to 12 hours at temperatures up to 30 °C. Thawed vials can be handled in room light conditions.

Preparation of 0.3 mL doses

- Gently mix by inverting vials 10 times prior to use. Do not shake.
- Prior to mixing, the thawed dispersion may contain white to off-white opaque amorphous particles.
- After mixing, the vaccine should present as a white to off-white dispersion with no particulates visible. Do not use the vaccine if particulates or discolouration are present.
- Check whether the vial is a single dose vial or a multidose vial and follow the applicable handling instructions below:
 - Single dose vials
 - Withdraw a single 0.3 mL dose of vaccine.
 - Discard vial and any excess volume.
 - Multidose vials
 - Multidose vials contain 6 doses of 0.3 mL each.
 - Using aseptic technique, cleanse the vial stopper with a single use antiseptic swab.
 - Withdraw 0.3 mL of Comirnaty JN.1.
 - **Low dead-volume syringes and/or needles** should be used in order to extract 6 doses from a single vial. The low dead-volume syringe and needle combination should have a dead-volume of no more than 35 microlitres. If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial.

- Each dose must contain 0.3 mL of vaccine.
- If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
- Record the appropriate date/time on the vial. Discard any unused vaccine 12 hours after first puncture.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Package leaflet: Information for the user

Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection Adults and adolescents from 12 years COVID-19 mRNA Vaccine raxtozinameran

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Comirnaty Omicron XBB.1.5 is and what it is used for
2. What you need to know before you receive Comirnaty Omicron XBB.1.5
3. How Comirnaty Omicron XBB.1.5 is given
4. Possible side effects
5. How to store Comirnaty Omicron XBB.1.5
6. Contents of the pack and other information

1. What Comirnaty Omicron XBB.1.5 is and what it is used for

Comirnaty Omicron XBB.1.5 is a vaccine used for preventing COVID-19 caused by SARS-CoV-2.

Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection is given to adults and adolescents from 12 years of age and older.

The vaccine causes the immune system (the body's natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.

As Comirnaty Omicron XBB.1.5 does not contain the virus to produce immunity, it cannot give you COVID-19.

The use of this vaccine should be in accordance with official recommendations.

2. What you need to know before you receive Comirnaty Omicron XBB.1.5

Comirnaty Omicron XBB.1.5 should not be given

- if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you are given the vaccine if:

- you have ever had a severe allergic reaction or breathing problems after any other vaccine injection or after you were given this vaccine in the past.
- you are feeling nervous about the vaccination process or have ever fainted following any needle injection.

- you have a severe illness or infection with high fever. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold.
- you have a bleeding problem, you bruise easily or you use a medicine to prevent blood-clots.
- you have a weakened immune system, because of a disease such as HIV infection or a medicine such as corticosteroid that affects your immune system.

There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) after vaccination with Comirnaty (see section 4). These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. The risk of myocarditis and pericarditis seems lower in children ages 5 to 11 years compared with ages 12 to 17 years. Most cases of myocarditis and pericarditis recover. Some cases required intensive care support and fatal cases have been seen. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur.

As with any vaccine, Comirnaty Omicron XBB.1.5 may not fully protect all those who receive it and it is not known how long you will be protected.

The efficacy of Comirnaty Omicron XBB.1.5 may be lower in people who are immunocompromised. If you are immunocompromised, you may receive additional doses of Comirnaty Omicron XBB.1.5. In these cases, you should continue to maintain physical precautions to help prevent COVID-19. In addition, your close contacts should be vaccinated as appropriate. Discuss appropriate individual recommendations with your doctor.

Children

Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection is not recommended for children aged under 12 years.

There are paediatric formulations available for infants aged 6 months and above and children below 12 years of age. For details, please refer to the Package Leaflet for other formulations.

The vaccine is not recommended for infants aged under 6 months.

Other medicines and Comirnaty Omicron XBB.1.5

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines or have recently received any other vaccine.

Comirnaty Omicron XBB.1.5 may be given at the same time as a flu vaccine.

In adults 18 years of age and older, Comirnaty Omicron XBB.1.5 may be given at the same time as a pneumococcal conjugated vaccine (PCV).

In adults 18 years of age and older, Comirnaty Omicron XBB.1.5 may be given at the same time as a respiratory syncytial virus (RSV) vaccine.

In older adults 65 years of age and older, Comirnaty Omicron XBB.1.5 may be given at the same time as a high dose flu and an RSV vaccine.

Pregnancy and breast-feeding

If you are pregnant or think you may be pregnant, tell your doctor, nurse or pharmacist before you receive this vaccine.

No data are available yet regarding the use of Comirnaty Omicron XBB.1.5 during pregnancy. However, a large amount of information from pregnant women vaccinated with the initially approved Comirnaty vaccine during the second and third trimester have not shown negative effects on the pregnancy or the newborn baby. While information on effects on pregnancy or the newborn baby after vaccination during the first trimester is limited, no change to the risk for miscarriage has been seen. Comirnaty Omicron XBB.1.5 can be used during pregnancy.

No data are available yet regarding the use of Comirnaty Omicron XBB.1.5 during breast-feeding. However, no effects on the breastfed newborn/infant are anticipated. Data from women who were breast-feeding after vaccination with the initially approved Comirnaty vaccine have not shown a risk for adverse effects in breastfed newborns/infants. Comirnaty Omicron XBB.1.5 can be used while breast-feeding.

Driving and using machines

Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your ability to drive or use machines. Wait until these effects have worn off before you drive or use machines.

3. How Comirnaty Omicron XBB.1.5 is given

Comirnaty Omicron XBB.1.5 is given as an injection of 0.3 mL into a muscle of your upper arm.

You will receive 1 injection, regardless whether you have received a COVID-19 vaccine before.

If you were previously vaccinated with a COVID-19 vaccine, you should not receive a dose of Comirnaty Omicron XBB.1.5 until at least 3 months after the most recent dose.

If you are immunocompromised, you may receive additional doses of Comirnaty Omicron XBB.1.5.

If you have any further questions on the use of Comirnaty Omicron XBB.1.5, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all vaccines, Comirnaty Omicron XBB.1.5 can cause side effects, although not everybody gets them.

Very common side effects: may affect more than 1 in 10 people

- injection site: pain, swelling
- tiredness, headache
- muscle pain, joint pain
- chills, fever
- diarrhoea

Some of these side effects were slightly more frequent in adolescents 12 to 15 years than in adults.

Common side effects: may affect up to 1 in 10 people

- nausea
- vomiting ('very common' in pregnant women 18 years of age and older and in immunocompromised individuals 12 to 18 years of age)
- injection site redness ('very common' in immunocompromised individuals 12 years of age and older)
- enlarged lymph nodes (more frequently observed after a booster dose)

Uncommon side effects: may affect up to 1 in 100 people

- feeling unwell, feeling weak or lack of energy/sleepy
- arm pain
- insomnia
- injection site itching
- allergic reactions such as rash or itching
- decreased appetite
- dizziness
- excessive sweating, night sweats

Rare side effects: may affect up to 1 in 1 000 people

- temporary one sided facial drooping
- allergic reactions such as hives or swelling of the face

Very rare side effects: may affect up to 1 in 10 000 people

- inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart (pericarditis) which can result in breathlessness, palpitations or chest pain

Not known (cannot be estimated from the available data)

- severe allergic reaction
- extensive swelling of the vaccinated limb
- swelling of the face (swelling of the face may occur in patients who have had facial dermatological fillers)
- a skin reaction that causes red spots or patches on the skin, that may look like a target or "bulls-eye" with a dark red centre surrounded by paler red rings (erythema multiforme)
- unusual feeling in the skin, such as tingling or a crawling feeling (paraesthesia)
- decreased feeling or sensitivity, especially in the skin (hypoaesthesia)
- heavy menstrual bleeding (most cases appeared to be non-serious and temporary in nature)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via HPRA Pharmacovigilance. Website: www.hpra.ie

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Comirnaty Omicron XBB.1.5

Keep this medicine out of the sight and reach of children.

The following information about storage, expiry and use and handling is intended for healthcare professionals.

Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.

Store in freezer at -90 °C to -60 °C.

Store in the original package in order to protect from light.

The vaccine will be received frozen at -90 °C to -60 °C. Frozen vaccine can be stored either at -90 °C to -60 °C or 2 °C to 8 °C upon receipt.

Single dose vials: When stored frozen at -90 °C to -60 °C, 10-vial packs of single dose vials of the vaccine can be thawed at 2 °C to 8 °C for 2 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Multidose vials: When stored frozen at -90 °C to -60 °C, 10-vial packs of the vaccine can be thawed at 2 °C to 8 °C for 6 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Thawed (previously frozen) vials: Once removed from the freezer, the unopened vial may be stored and transported refrigerated at 2 °C to 8 °C for up to 10 weeks; not exceeding the printed expiry date (EXP). The outer carton should be marked with the new expiry date at 2 °C to 8 °C. Once thawed, the vaccine cannot be re-frozen.

Prior to use, the unopened vials can be stored for up to 12 hours at temperatures between 8 °C and 30 °C.

Thawed vials can be handled in room light conditions.

Opened vials: After first puncture, store the vaccine at 2 °C to 30 °C and use within 12 hours, which includes up to 6 hours transportation time. Discard any unused vaccine.

Do not use this vaccine if you notice particulates or discolouration.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Comirnaty Omicron XBB.1.5 contains

- The active substance of COVID-19 mRNA Vaccine (nucleoside modified) is called raxtozinameran.
 - A single dose vial contains 1 dose of 0.3 mL with 30 micrograms raxtozinameran each.
 - A multidose vial contains 6 doses of 0.3 mL with 30 micrograms raxtozinameran each.
- The other ingredients are:
 - ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
 - 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
 - 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)
 - cholesterol
 - trometamol
 - trometamol hydrochloride
 - sucrose
 - water for injections

What Comirnaty Omicron XBB.1.5 looks like and contents of the pack

The vaccine is a white to off-white dispersion (pH: 6.9 - 7.9) provided in either:

- A single dose vial of 1 dose in a 2 mL clear vial (type I glass), with a rubber stopper and a grey flip-off plastic cap with aluminium seal; or
- A multidose vial of 6 doses in a 2 mL clear vial (type I glass), with a rubber stopper and a grey flip-off plastic cap with aluminium seal.

Single dose vials pack size: 10 vials

Multidose vials pack sizes: 10 vials or 195 vials

Not all pack sizes may be marketed.

Marketing Authorisation Holder

BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz
Germany
Phone: +49 6131 9084-0
Fax: +49 6131 9084-2121
service@biontech.de

Manufacturers

BioNTech Manufacturing GmbH
Kupferbergterrasse 17 - 19
55116 Mainz
Germany

Pfizer Manufacturing Belgium NV
Rijksweg 12
Puurs-Sint-Amands, 2870
Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Ireland: Pfizer Healthcare Ireland, Tel: 1800 633 363 (toll free), +44 (0)1304 616161

This leaflet was last revised in 02/2025.

Scan the code with a mobile device to get the package leaflet in different languages.



URL: www.comirnatyglobal.com

Detailed information on this medicine is available on the European Medicines Agency website:
<https://www.ema.europa.eu>.

Ref: bCY (XBB.1.5) 30 mcg 9_0

The following information is intended for healthcare professionals only:

Administer Comirnaty Omicron XBB.1.5 intramuscularly as a single dose of 0.3 mL regardless of prior COVID-19 vaccination status.

For individuals who have previously been vaccinated with a COVID-19 vaccine, Comirnaty Omicron XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine.

Additional doses may be given to individuals who are severely immunocompromised.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Handling instructions prior to use

Comirnaty Omicron XBB.1.5 should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

- **Verify** that the vial has a **grey plastic cap** and the product **name is Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection** (12 years and older).
- If the vial has another product name on the label, please make reference to the Summary of Product Characteristics for that formulation.
- If the vial is stored frozen it must be thawed prior to use. Frozen vials should be transferred to an environment of 2 °C to 8 °C to thaw. Ensure vials are completely thawed prior to use.
 - Single dose vials: A 10-vial pack of single dose vials may take 2 hours to thaw.
 - Multidose vials: A 10-vial pack of multidose vials may take 6 hours to thaw.
- Upon moving vials to 2 °C to 8 °C storage, update the expiry date on the carton.
- Unopened vials can be **stored for up to 10 weeks at 2 °C to 8 °C**; not exceeding the printed expiry date (EXP).
- Alternatively, individual frozen vials may be thawed for 30 minutes at temperatures up to 30 °C.
- Prior to use, the unopened vial can be stored for up to 12 hours at temperatures up to 30 °C. Thawed vials can be handled in room light conditions.

Preparation of 0.3 mL doses

- Gently mix by inverting vials 10 times prior to use. Do not shake.
- Prior to mixing, the thawed dispersion may contain white to off-white opaque amorphous particles.
- After mixing, the vaccine should present as a white to off-white dispersion with no particulates visible. Do not use the vaccine if particulates or discolouration are present.
- Check whether the vial is a single dose vial or a multidose vial and follow the applicable handling instructions below:
 - Single dose vials
 - Withdraw a single 0.3 mL dose of vaccine.
 - Discard vial and any excess volume.
 - Multidose vials
 - Multidose vials contain 6 doses of 0.3 mL each.
 - Using aseptic technique, cleanse the vial stopper with a single use antiseptic swab.
 - Withdraw 0.3 mL of Comirnaty Omicron XBB.1.5.
 - **Low dead-volume syringes and/or needles** should be used in order to extract 6 doses from a single vial. The low dead-volume syringe and needle combination should have a dead-volume of no more than 35 microlitres. If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial.
 - Each dose must contain 0.3 mL of vaccine.
 - If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
 - Record the appropriate date/time on the vial. Discard any unused vaccine 12 hours after first puncture.

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.